// App-Quantinova.ai

325 : Activity of new agents (NAs) as third-line treatment in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) after a long-term disease control (LTDC) with abiraterone acetate (AA) or enzalutamide (ENZ) post docetaxel (DOC): Preliminary results from a multicenter Italian study.

Researchers

Presenter

  • Antonello Veccia

Principal Investigators

  • Gaetano Facchini

  • Lucia Fratino

  • Donatello Gasparro

  • Daniele Alesini

  • Umberto Basso

  • Marcello Tucci

  • Cinzia Ortega

  • Sarah Scagliarini

  • Francesco Verderame

  • Giovanni Lo Re

  • Giuseppe Procopio

  • Roberto Sabbatini

  • Enrico Campadelli

  • Paolo Andrea Zucali

  • Franco Morelli

  • Donata Sartori

  • Vincenza Conteduca

  • Orazio Caffo

Medical Centers

  • Santa Chiara Hospital, Trento, Italy

  • Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy

  • Division of Medical Oncology, Department of Uro-Gynaecological Oncology, Istituto Nazionale Tumori Fondazione G. Pascale - IRCCS, Naples, Italy, Naples, Italy

  • National Cancer Center CRO, Aviano, Italy

  • University Hospital of Parma, Parma, Italy

  • Division of Medical Oncology, Universit la Sapienza Roma, Rome, Italy

  • Medical Oncology Unit, Department of Clinical and Experimental Oncology, Istituto Oncologico Veneto IOV - IRCCS, Padova, Italy

  • Department of Oncology, AOU San Luigi Gonzaga, Orbassano (TO), Italy

  • Ospedale Mauriziano Umberto I di Torino e Istituto Per La Ricerca e La Cura del Cancro di Candiolo, Torino, Italy

  • Cardarelli Hospital, Naples, Italy

  • Cervello Hospital, Palermo, Italy

  • Santa Maria Degli Angeli General Hospital, Pordenone, Italy

  • Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

  • Azienda Ospedaliero-Universitaria, Udine, Italy

  • Civil Hospital, Lugo Di Romagna, Italy

  • Humanitas Cancer Center, IRCCS, Rozzano, Italy

  • U.O. Oncologia, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy

  • Azienda ULSS 13, Mirano, Italy

  • Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy

Locations

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • N/A

Drug/Treatment

  • CB-7598

  • Enzalutamide

  • Docetaxel

Outcome

  • N/A

Study Design

  • Multicenteric

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved